Resistance on Antithrombotic Drugs in Ischemic Heart Disease
Launched by UNIVERSITY OF ZAGREB · Aug 26, 2008
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
Our plan is to enroll 180 patients with diagnosed CAD who electively undergo percutaneous coronary intervention (PCI). Blood samples will be taken just before the procedure and one day after the procedure and analysed on Multiplate function analyser. Assessing aspirin and clopidogrel resistance incidence using Multiplate platelet function analyzer we will also try to find resistance correlation with the incidence of major adverse cardiac events in a one year follow up.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Elective PCI
- • \> 7 days on aspirin 100mg therapy before the intervention
- • \> 7 days on clopidogrel 75mg therapy before the intervention
- Exclusion Criteria:
- • Loading dose of clopidogrel
- • \< 7 days on aspirin therapy before the intervention
- • Myocardial infarction less than 30 days before the intervention
- • Cerebrovascular incident less that three months before the intervention
- • Haemorrhagic diathesis
- • Trc \< 100
- • Htc \< 30%
- • Creatinine \> 140
About University Of Zagreb
The University of Zagreb, a leading academic institution in Croatia, is committed to advancing medical research and improving healthcare outcomes through innovative clinical trials. With a focus on interdisciplinary collaboration, the university harnesses its extensive expertise and state-of-the-art facilities to conduct rigorous clinical studies that address pressing health challenges. By fostering partnerships with healthcare professionals, industry leaders, and regulatory bodies, the University of Zagreb aims to translate scientific discoveries into practical applications, ultimately enhancing patient care and contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zagreb, , Croatia
Patients applied
Trial Officials
Davor Milicic, prof.dr.sc.
Principal Investigator
Clinic of Cardiovascular Diseases, Clinical Medical Centre Rebro, Zagreb, Croatia
Bosko Skoric, dr.
Study Chair
Clinic of Cardiovascular Diseases, Clinical Medical Centre Rebro, Zagreb, Croatia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials